...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Journal of stroke and cerebrovascular diseases: The official journal of National Stroke Association >New Developments in Secondary Stroke Prevention: Impact of the European/Australasian Stroke Prevention in Reversible Ischemia Trial (ESPRIT) on Clinical Management
【24h】

New Developments in Secondary Stroke Prevention: Impact of the European/Australasian Stroke Prevention in Reversible Ischemia Trial (ESPRIT) on Clinical Management

机译：二级卒中预防的新进展：可逆性缺血性试验中欧洲/澳大利亚卒中预防对临床治疗的影响

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Secondary stroke prevention is an important goal of poststroke patient treatment. Various pharmacologic approaches have been advocated, but the relative efficacy and safety of these regimens has remained the subject of much debate. Recently released data from the European/Australasian Stroke Prevention in Reversible Ischemia Trial (ESPRIT) indicated that combination therapy with aspirin and extended-release dipyridamole was more effective than aspirin monotherapy, and probably more effective than anticoagulants, for the prevention of cerebrovascular events after a stroke or transient ischemic attack. When viewed in light of results of earlier trials, these findings confirmed that combination aspirin plus extended-release dipyridamole therapy improved outcomes in these patients and is a recommended option for poststroke patient treatment.
机译：预防中风是中风后患者治疗的重要目标。已经提倡各种药理学方法，但是这些方案的相对效力和安全性仍然是许多争论的主题。欧洲/澳大利亚的可逆性缺血性卒中预防试验（ESPRIT）最近发布的数据表明，阿司匹林和缓释双嘧达莫联合治疗比单用阿司匹林更有效，并且可能比抗凝药更有效，以预防脑梗死后的脑血管事件中风或短暂性脑缺血发作。从早期试验的结果来看，这些发现证实阿司匹林加缓释双嘧达莫联合治疗可改善这些患者的预后，是卒中后患者治疗的推荐选择。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号